Compounds advantageous in the treatment of central nervous system diseases and disorders

• US 9,212,155 B2
• Filed: 09/13/2010
• Issued: 12/15/2015
• Est. Priority Date: 03/19/2008
• Status: Active Grant

• Current Assignee: AurimMed Pharma, Inc.
• Original Assignee: AurimMed Pharma, Inc.
• Inventors: Pesyan, Amir, Balandrin, Manuel F.
• Primary Examiner(s): Chang, Celia
• Application Number:
  US12/881,068
• Publication Number:
  US 20110046128A1
• Time in Patent Office: 1,919 Days
• Field of Search: 564/347, 564/374, 564/155, 564/167, 564/175, 564/182, 514/553, 514/557, 514/613, 514/625, 514/231.2, 514/617, 514/522, 514/622
• US Class Current: 1/1
• CPC Class Codes: A61K 31/165 having aromatic rings, e.g. colchicine, atenolol, progabide
• CPC Class Codes: A61K 31/353 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• CPC Class Codes: A61K 31/36 Compounds containing methylenedioxyphenyl groups, e.g. sesamin
• CPC Class Codes: A61K 31/44 Non condensed pyridines; Hydrogenated derivatives thereof
• CPC Class Codes: A61K 31/445 Non condensed piperidines, e.g. piperocaine
• CPC Class Codes: A61K 31/495 having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazinesA61K31/48 takes precedence ; with three nitrogen atoms A61K31/53
• CPC Class Codes: A61K 31/5375 1,4-Oxazines, e.g. morpholine
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: C07D 295/155 with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Abstract

A series of novel compounds showing anticonvulsant, chemical countermeasure(s), and analgesic activities is described. Such pharmaceutically active compounds may also show utility in the treatment of other central nervous system (“CNS”) diseases and disorders, such as anxiety, depression, insomnia, migraine headaches, schizophrenia, Parkinson'"'"'s disease, spasticity, Alzheimer'"'"'s disease, and bipolar disorder. Furthermore, such compounds may additionally find utility as analgesics (e.g., for the treatment of chronic or neuropathic pain) and as neuroprotective agents useful in the treatment of stroke(s), chronic neurodegenerative diseases (such as Alzheimer'"'"'s disease and Huntington'"'"'s disease), and/or traumatic brain and/or spinal cord injuries. Moreover, these/such compounds may also be useful in the treatment of status epilepticus and/or as chemical countermeasures.

Claims

1. A pharmaceutical composition, comprising a therapeutically effective amount of at least one compound of Formula BX or Formula BY admixed with at least one of a pharmaceutically acceptable carrier or an excipient

2. The pharmaceutical composition as in claim 1, wherein the therapeutically effective amount of at least one of Formula BX or Formula BY ranges from 22.5 mg/kg to 200 mg/kg.

3. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula BX admixed with at least one of a pharmaceutically acceptable carrier or an excipient

4. A composition for treating or preventing acute or chronic pain comprising an analgesic effective amount at least one of

5. A composition for treating or preventing convulsion or seizure comprising an anticonvulsant effective amount at least one of